Alternative splicing of HER2: a novel mediator of EGFR TKI resistance

被引：1
|
作者：
Yochum, Zachary A. [1 ,2 ]
Villaruz, Liza C. [1 ]
机构：
[1] UPMC Hillman Canc Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Med Scientist Training Program, Pittsburgh, PA USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 04期
关键词：
CELL LUNG-CANCER; PHASE-III; BREAST-CANCER; OPEN-LABEL; 1ST-LINE; AMPLIFICATION; OSIMERTINIB; MUTATION;
D O I：
10.21037/tlcr-20-618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1606 / 1612
页数：7
相关论文
共 50 条
  • [31] The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors
    Cirstea, Andreea-Elena
    Stepan, Alex Emilian
    Margaritescu, Claudiu
    Zavoi, Roxana Eugenia
    Olimid, Daniel Alin
    Simionescu, Cristiana Eugenia
    ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2017, 58 (04) : 1269 - 1273
  • [32] The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer
    Kim, S. T.
    Do, I. -G.
    Lee, J.
    Sohn, I.
    Kim, K. -M.
    Kang, W. K.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2015, 17 (06) : 462 - 468
  • [33] TAS2940, a novel brain-penetrable pan-ERBB inhibitor, for tumors with HER2 and EGFR aberrations
    Oguchi, Kei
    Araki, Hikari
    Tsuji, Shingo
    Nakamura, Masayuki
    Miura, Akihiro
    Funabashi, Kaoru
    Osada, Akiko
    Tanaka, Sakiho
    Suzuki, Takamasa
    Kobayashi, Susumu S.
    Mizuarai, Shinji
    CANCER SCIENCE, 2023, 114 (02) : 654 - 664
  • [34] Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
    Borrero-Garcia, Luis D.
    del Mar Maldonado, Maria
    Medina-Velazquez, Julia
    Troche-Torres, Angel L.
    Velazquez, Luis
    Grafals-Ruiz, Nilmary
    Dharmawardhane, Suranganie
    BMC CANCER, 2021, 21 (01)
  • [35] Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
    Luis D. Borrero-García
    Maria del Mar Maldonado
    Julia Medina-Velázquez
    Angel L. Troche-Torres
    Luis Velazquez
    Nilmary Grafals-Ruiz
    Suranganie Dharmawardhane
    BMC Cancer, 21
  • [36] A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2-advanced breast cancer patients with HER2 mutations
    Ma, Jing
    Li, Xuelu
    Zhang, Qianran
    Li, Ning
    Sun, Siwen
    Zhao, Shanshan
    Zhao, Zuowei
    Li, Man
    TRANSLATIONAL ONCOLOGY, 2022, 21
  • [37] Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
    Canonici, Alexandra
    Gijsen, Merel
    Mullooly, Maeve
    Bennett, Ruth
    Bouguern, Noujoude
    Pedersen, Kasper
    O'Brien, Neil A.
    Roxanis, Ioannis
    Li, Ji-Liang
    Bridge, Esther
    Finn, Richard
    Slamon, Dennis
    McGowan, Patricia
    Duffy, Michael J.
    O'Donovan, Norma
    Crown, John
    Kong, Anthony
    ONCOTARGET, 2013, 4 (10) : 1592 - 1605
  • [38] Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
    Peng, Zhi
    Liu, Yi
    Li, Yanyan
    Zhang, Xiaotian
    Zhou, Jun
    Lu, Ming
    Li, Qingqing
    Shen, Lin
    BIOMARKERS IN MEDICINE, 2014, 8 (05) : 663 - 670
  • [39] Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer
    Olsen, Dorte Aa.
    Jakobsen, Erik H.
    Brandslund, Ivan
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (12) : 2325 - 2329
  • [40] EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria
    Orekoya, Ajibike Ayomide
    Abdus-Salam, Abbas A.
    Oyesegun, Abdurasaq R.
    Ntekim, Atara, I
    Folasire, Ayorinde M.
    Okolo, Clement A.
    Olabumuyi, Adeniyi A.
    Dada, Adedamola A.
    Adenipekun, Adeniyi A.
    ECANCERMEDICALSCIENCE, 2023, 17
12345